August 19, 2016
FDA has issued a Warning Letter to Noven Pharmaceuticals, Inc. (Miami, FL) pointing to a number of problems with measurement, analysis and testing, as well as insufficient attention to customer complaints and their root causes.
Customer complaints for one product reportedly increased by 50% from 2013 to 2014, inspectors noted, but Noven had failed to determine the root causes of problems. Inspectors trace that to inadequate testing methods.
Noven’s staff members had also failed to validate test methods to detect adhesive transfer, FDA said, which would remove the drug from the product, rendering it unusable.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.